Pfizer Signs $1.5 Billion Deal With Blackstone to Fund Weight-Loss-Drug Development
Pfizer secures up to $1.5 billion from Blackstone Life Sciences to advance a once-monthly GLP-1 obesity treatment acquired from Metsera.
19 trends tracked about this subject — the full history, oldest to newest below.
Pfizer secures up to $1.5 billion from Blackstone Life Sciences to advance a once-monthly GLP-1 obesity treatment acquired from Metsera.
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Pfizer CEO touts massive deal volume and a raised profit forecast amid strong quarterly earnings reports.
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Pfizer raises its full-year outlook and beats Q3 expectations as it pivots toward cancer and weight-loss medications in a post-pandemic recovery.
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Pfizer has increased its 2026 full-year guidance following strong third-quarter results driven by growth in cancer and migraine medications.
8 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Vaxcyte stock surges following phase 3 trial results for its pneumococcal vaccine candidate in a lucrative market.
Health authorities and medical groups are updating guidance for the 2026 fall respiratory vaccine season, including new cost structures in Australia.
The US FDA has approved Pfizer and BioNTech’s XFG-adapted COVID-19 vaccine as updated shots become available to the public.
Pfizer has adjusted its 2026 revenue guidance upward following the release of its second-quarter financial results.
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Pfizer's stock is rising after beating earnings estimates, despite a 95% plunge in revenue from its Covid pill.
AstraZeneca shares dropped six percent following a heart drug trial setback that simultaneously boosted rival stocks.
A US House committee has launched an investigation into major pharmaceutical companies regarding the use of clinical trial sites in China.
8 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.